Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019 Nov 6, 2019
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment Oct 28, 2019
Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th Oct 24, 2019
Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts Sep 23, 2019
Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment Sep 16, 2019
Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference Sep 5, 2019
Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B Jul 23, 2019
Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers Jul 11, 2019
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting Jun 26, 2019
